Martin Borch Jensen is a scientist, entrepreneur and longevity advocate. He is the co-founder and CSO of Gordian Biotechnology, a company whose platform enables the simultaneous delivery and testing of hundreds of therapeutics in individual animals. They have raised over $60M from top investors like Founders Fund, Horizons Ventures, Fifty Years and the Longevity Fund. They also recently announced a partnership with Pfizer to apply Gordian’s proprietary mosaic screening platform to accelerate the discovery of therapeutic targets for obesity.

Martin is also a prominent voice in the longevity community and activist. As founder and president of Norn Group, a do tank for longevity, he launched the Impetus Grants program, which has deployed roughly $34 million to scientists across 145 projects, with funding decisions made within 3 weeks to enable speed.

In our conversation today, we cover the state of the longevity field, its major bottlenecks, theories of aging, the role of AI in longevity, and much more.

Today’s guest is Karl Pfleger. After spending a decade as one of the first AI researchers at Google from 2002 to 2011, he has dedicated himself to the cause of rejuvenation biotechnology for nearly a decade. He is a philanthropist, community builder, and prolific angel investor with over 35 investments into rejuvenation biotech startups. His website, agingbiotech.info, provides valuable information to the entire field, and his talks and X posts are highly insightful and influential within longevity.

Karl has deeply researched and nuanced takes, and those really show in this conversation. We’ll cover why epigenetic reprogramming won’t solve aging, Karl’s investment strategy and what distinguishes true rejuvenation technology, and why better diagnostic technologies could be the key to personalized aging interventions.

Dr. Daniel Ives is the founder of Shift Bioscience. Shift has built a novel single-cell aging clock that has enabled them to run high-throughput screens to discover genes that regulate aging, with the goal of identifying a therapy to systemically reverse aging.

We’ll dive deep into Shift’s latest work on SB000, a germline-expressed gene that rejuvenates cells without inducing pluripotency, and SB101, a pro-aging gene whose inhibition both reverses cellular age and prevents fibrosis, opening a clear path to clinical development.

Daniel also shares his philosophy on why reversing aging might be easier than we think, the coming cultural shift when anti-aging drugs become mundane reality, and why he won't rest until we can double human lifespan.